
# Probabilistic computer-aided diagnosis of Alzheimer's disease and frontotemporal dementia based on MRI and biochemical markers

#### Agnès Pérez-Millan<sup>a,b</sup>, Bertrand Thirion<sup>c</sup>, Sergi Borrego-Écija<sup>a</sup>, José Contador<sup>a</sup>, Jordi Juncà-Parell<sup>a</sup>, Raquel Ruiz-Garcia<sup>d</sup>, Laura Naranjo<sup>d</sup>, Mircea Balasa<sup>a</sup>, Albert Lladó<sup>a</sup>, Roser Sala-Llonch<sup>b</sup>, Raquel Sánchez-Valle<sup>a</sup>

<sup>a</sup>Alzheimer's disease and other cognitive disorders unit, Neurology Service, Hospital Clínic de Barcelona, Spain <sup>c</sup>Inria, CEA, Université Paris-Saclay, Paris, France <sup>d</sup>Immunology Department, Biomedical Diagnostic Center, Hospital Clínic, Barcelona, Spain

### BACKGROUND

Neuroimaging and fluid biomarkers are used in clinics to differentiate frontotemporal dementia (FTD) from Alzheimer's disease (AD) and other neurodegenerative and non-neurodegenerative disorders. We implemented a machine learning (ML) algorithm that provides individual probabilistic scores for FTD and AD based on magnetic resonance imaging (MRI).




We used the 3T MRI images of 215 AD patients (65 ± 10 years, 137 women), 103 FTD patients  $(64 \pm 8 \text{ years}, 49 \text{ women})$ , and 173 CTR  $(59 \pm 15 \text{ years}, 106 \text{ women})$ . We used the individual probabilities to address the clinical problem of confidence in the diagnosis. We investigated whether combining MRI and cerebrospinal fluid (CSF) levels of NfL and 14-3-3 could improve the diagnosis confidence.

## CONCLUSIONS

Our ML approach provides individual probabilities and holds promise toward individual diagnoses, especially in doubtful cases as support to clinical findings or in settings with limited access to expert diagnoses.

#### **Contact Information: Agnès Pérez-Millan**

M <u>agperez@recerca.clinic.cat</u> @agnesperezmi



2. Adding CSF-NfL and 14-3-3 levels did not improve the accuracy or the number of patients in the high diagnosis confidence group [Table 1 & Figure 3].


	AD vs CTR	FTD vs CTR	AD vs FTD
MRI all data	Accuracy: 87.7%	Accuracy: 86.9%	Accuracy: 81.8%
(N=491)	AD: 73.4%	FTD: 74.2%	AD: 73.3%
	CTR: 64.5%	CTR: 73.3%	FTD: 74.2%
MRI reduced	Accuracy: 88.5%	Accuracy: 85.6%	Accuracy: 84.6%
data	AD: 67.2%	FTD: 68.1%	AD: 53.2%
(N=178)	CTR: 55.3%	CTR: 54.3%	FTD: 54.4%
CSF data	Accuracy: 93.0%	Accuracy: 86.6%	Accuracy: 83.8%
(N=178)	AD: 72.1%	FTD: 72.1%	AD: 40.6%
	CTR: 71.7%	CTR: 23.5%	FTD: 45.9%
MRI and CSF data	Accuracy: 90.3%	Accuracy: 86.5%	Accuracy: 88.5%
(N=178)	AD: 68.1%	FTD: 70.8%	AD: 60.7%
	CTR: 64.4%	CTR: 53.2%	FTD: 55.1%

**Table 1:** Classification performance of the different approaches and the percentage of participants with a higher probability of 0.8 in the diagnosis grouped by diagnosis.

Agnès Pérez-Millan is a recipient of the French Embassy in Spain / Institut français de España fellowship and a travel fellowship from María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) MDM-2017-0729. This work was supported by Instituto de Salud Carlos III, Spain (grant no. PI20/0448 to Dr. R. Sanchez-Valle, PI19/00449 to Dr. A. Lladó and project PI19/00198 to Dr. M. Balasa, AGAUR, Generalitat de Catalunya (SGR 2021-01126) and by Spanish Ministry of Science and Innovation (PID2020-118386RA-I00/ AEI/10.13039/501100011033 to Dr. R. Sala-Llonch), and KARAIB AI chair (ANR-20-CHIA-0025-01) and the H2020 Research Infrastructures Grant EBRAIN-Health 101058516 to Dr. B. Thirion. The authors thank the patients and their relatives for participating in the study.



1. We obtained accuracies of 88% in the AD vs. CTR, 87% for FTD vs. CTR, 82% for AD vs. FTD, and 80% when differentiating the three groups. A total of 74% of FTD and 73% of AD participants have a high (≥0.8) probability of accurate diagnosis in the FTD vs. AD comparison [Figures 1 & 2].







Clínic arcelona

Institut de Neurociències